A U.S. federal judge has denied an injunction that would have allowed compounding pharmacies to keep making copies of Eli Lilly's popular weight-loss drug Zepbound in the U.S. The decision was filed late on Wednesday in response to an October lawsuit from a compounding industry group against the U.

A federal judge has effectively ended the ability of compounding pharmacies to make their own copies of Eli Lilly’s weight loss and diabetes drugs Zepbound and Mounjaro. In a sealed decision

As a federal court in Texas hears a case pitting the FDA versus compounders who want to continue to manufacture cheaper knockoff versions of popular weight loss drugs, Novo Nordisk will not have to | A federal district court in Texas will allow Novo Nordisk to intervene in a lawsuit pitting compounders against the FDA.

Novo Nordisk is intervening in the lawsuit filed by a drug compounders trade group against the FDA over the agency’s decision to declare the Wegovy shortage over. Eli Lilly did the same in a parallel case over Zepbound’s removal from the FDA shortage list and this week a judge denied

The sale of compounded versions of Eli Lilly's LLY.N rival obesity and diabetes drugs, Zepbound and Mounjaro, was banned in December after the FDA found them to no longer be in short supply. The FDA said in a statement that compounding pharmacies ...

Morgan Stanley noted that two compounding groups – the Outsourcing Facilities Association and North American Custom Laboratories – filed a

After scoring a long-awaited FDA approval last fall, Eli Lilly has launched a consumer-facing campaign to get the word out about its atopic dermatitis treatment Ebglyss.

The partnership comes as telehealth companies grapple with restrictions on the sale of some compounded GLP-1s.

Telehealth firms Teladoc Health and LifeMD said on Thursday they have signed an agreement with Eli Lilly's direct-to-consumer website LillyDirect pharmacy partner, Gifthealth, to offer patients the weight-loss drug,

Eli Lilly is now offering four doses of Zepbound in self-administration vials. The lower-cost self-pay option targets people on Medicare and those who can no longer access compounded tirzepatide.

Eli Lilly is seeking to further cement its stance as a leader in weight loss drugs in an ad campaign calling out “unapproved” medications.

A U.S. federal judge has refused to allow compounding pharmacies to keep making copies of Eli Lilly's popular weight-loss and diabetes drugs Zepbound and Mounjaro in the United States.